myelomaThis report summarizes the 5th annual symposium on minimal residual disease (MRD) testing in multiple myeloma gathered experts from academia, industry and the FDA in New York City on 14 September 2018. Three recommendations were made: (a) MRD testing should be performed in patients who ...
Overview of Bispecifics for R/R Multiple Myeloma Patient Profile: A 72-Year-Old Man With RRMMPodcasts Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM Advancing Myeloma Treatment With Blood-Based MRD Testing
EP: 6.An Overview of Minimal Residual Disease Testing EP: 7.How to Properly Utilize MRD Testing EP: 8.Varying Pertinence: MRD Testing Across Lymphomas EP: 9.Reliability of MRD Testing: Sensitivity/Specificity Now Viewing EP: 10.MRD Negativity in Multiple Myeloma EP: 11.The Value of MRD...
“By testing in serum with equivalent sensitivity to bone marrow, we will solve current challenges in multiple myeloma MRD-testing, allowing for a more frequent and reliable monitoring of response to treatment.” Sebia is currently the only global partner covering the process of M-protein testing ...
Healio presents take home video interviews with multiple myeloma experts from the ASH Annual Meeting and ASCO Annual Meeting.
[complete response], whether it’s pretransplant, 3 months post-transplant, or a year post-transplant, we do MRD testing routinely. That is our clinical practice. We try not to make any clinical decisions based on it. But our goal is to get to MRD negative specifically for the high-...
Minimal residual disease (MRD) testing in newly diagnosed multiple myeloma (MM) patients: a prospective head-to-head assessment of cell-based, molecular, and molecular-imaging modalities. Blood. 2014;124(21). abstract 2105.Google Scholar 40. Takamatsu Murata R,, Zheng J, et al. Prognostic ...
The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
Purpose: multiple myeloma is considered an incurable hematologic cancer but a subset of patients can achieve long-term remissions and survival. The present study examines the clinical features of long-term survival as it correlates to depth of disease re
MRD is a measure of how deep a remission you can achieve in a patient with multiple myeloma. There are 2 primary assays that are used to assess this: one is flow cytometry, where you’re looking with various markers on plasma cells to see how many residual cells there are at the end ...